13 results about "Colon inflammation" patented technology

This invention belongs to the field of biomedicine, specifically relating to small interfering RNA (sRNA) targeting the TNF-α gene; it includes a sense strand and an antisense strand; the sense strand and / or the antisense strand has a length ranging from 19 to 25 nucleotides, and the antisense strand is inversely complementary to a segment on the target gene. Furthermore, it achieves drug delivery of the small interfering RNA through a specific target gene, enabling precise drug targeting at the site of colonic inflammation, enhancing the therapeutic effect of IBD without causing systemic immunosuppression, thus providing a more precise and efficient gene regulation tool.

The present application relates to the technical field of microorganism, in particular to a leuconostoc lactis with good probiotic characteristics and application thereof in preparation of drugs for preventing and treating inflammatory bowel disease, and the leuconostoc lactis (Leuconostoc lactis) LL271 provided by the present application is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 25974.The strain has good acid tolerance, bile salt tolerance, self-aggregation ability, hydrophobicity and other probiotic characteristics such as the ability to inhibit common human pathogenic microorganisms; meanwhile, the strain can improve intestinal inflammation, has prevention and treatment effects on inflammatory bowel disease, has high biological safety, can be used as probiotic preparation for relieving inflammatory bowel disease, improving intestinal mucosal injury and colon inflammation, provides a new strategy for preventing and treating inflammatory bowel disease, and has a potential clinical application prospect.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

The application provides a lactobacillus plantarum DX7 and a method and application thereof for producing indole lactic acid, relates to the field of food microbial technology, and the lactobacillus plantarum DX7 has been preserved in the Guangdong Microbial Culture Collection Center on June 12, 2025, and the preservation number is GDMCC NO.66498. The lactobacillus plantarum DX7 in the application is significantly activated under the stimulation of deep-line walnut inner seed coat polyphenol, and can efficiently convert tryptophan into ILA. Experimental results show that the ILA yield of the strain reaches 217.56 mu g / mL. Moreover, the strain and deep-line walnut inner seed coat polyphenol can significantly relieve the colon inflammation symptoms of a DSS-induced colon inflammation mouse by gavage. The application not only provides a new strategy for efficient biological preparation of the functional component ILA, but also provides a basis and potential solution for dietary intervention of inflammatory bowel disease.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

This invention discloses a nanoemulsion gel containing Sichuan pepper volatile oil, its preparation method, and its application. The Sichuan pepper volatile oil nanoemulsion gel of this invention comprises a core layer and an encapsulation layer. The core layer is a nanoemulsion loaded with Sichuan pepper volatile oil, and the encapsulation layer is a carboxymethyl chitosan-sodium alginate composite hydrogel. The composite hydrogel forms a three-dimensional network structure through calcium ion cross-linking, encapsulating the Sichuan pepper volatile oil-loaded nanoemulsion within it. This invention prepares Sichuan pepper volatile oil into a nanoemulsion, significantly improving its water solubility and chemical stability, and reducing degradation in the gastrointestinal tract after oral administration. Further encapsulation with the carboxymethyl chitosan-sodium alginate composite hydrogel utilizes the pH sensitivity and colonic enzyme responsiveness of the composite hydrogel to reduce drug release in the stomach and small intestine, allowing the drug to degrade and release upon reaching the colon, thus increasing drug accumulation at sites of colonic inflammation. This solves the problems of poor targeting and low bioavailability of Sichuan pepper volatile oil.

The present application relates to the field of microbial technology, and particularly relates to a bacterium El1405 and application thereof in bacteriostasis and anti-inflammation. The bacterium has a preservation number of CGMCC No.31231. The application includes bacteriostasis and anti-inflammation, and the microorganism includes one or more of Listeria monocytogenes, Staphylococcus aureus, Salmonella typhimurium or Escherichia coli. The bacterium can relieve various infection symptoms caused by Salmonella infection, and shows potential in preparation of a drug for treatment and / or prevention of infection of pathogenic bacteria such as Salmonella. The bacterium can also effectively relieve inflammatory bowel disease, reduce intestinal mucosal damage and colon inflammation symptoms, and provide a new strategy for prevention and treatment of inflammatory bowel disease, and has potential clinical application prospect.

The application is a colon-targeting lipid nanoparticle based on ginsenoside Rg3, a calcium alginate microsphere thereof and application thereof in treating ulcerative colitis, and belongs to the technical field of new excipients and new dosage forms of pharmaceutical preparations, and particularly relates to an oral colon-targeting delivery system for treating ulcerative colitis. The system replaces cholesterol in traditional lipid nanoparticles with ginsenoside Rg3, constructs lipid nanoparticles capable of efficiently loading TNF-alpha siRNA, and effectively improves the targeting property and lysosome escape ability of the lipid nanoparticles on inflammatory macrophages. In order to further realize colon-specific delivery, the above-mentioned lipid nanoparticles are loaded in a pH-responsive calcium alginate microsphere, so that the drug is kept stable in the upper gastrointestinal tract and is released in a responsive manner in the colon. Pharmacodynamic studies show that the drug delivery system can significantly relieve the symptoms of colitis, effectively silence the expression of TNF-alpha, repair the intestinal barrier, and regulate the intestinal microbiota. The application provides a safe and efficient new strategy for solving the problems of poor gastrointestinal stability and low targeting efficiency of oral delivery of nucleic acid drugs.

The application discloses a hydrogen sulfide responsive carbon monoxide donor molecule, a preparation method and application thereof. The hydrogen sulfide responsive carbon monoxide donor molecule has the structure shown in the following formula: wherein R1, R2, R3 and R4 are independently selected from an electron-withdrawing group, an electron-donating group or a hydrogen atom, and X is selected from O or the application provides a hydrogen sulfide responsive carbon monoxide donor molecule, which is designed in structure, acyloxy diene-Fe(CO)3 is selected as a carbon monoxide releasing unit, and an azido group is selected as a hydrogen sulfide responsive unit; the donor molecule formed by the two units has hydrogen sulfide responsiveness, can release carbon monoxide in the presence of hydrogen sulfide, can adjust the hydrogen sulfide response rate of the donor material and the release rate of carbon monoxide, and can further realize the treatment of colon inflammation and the inhibition of colorectal cancer.

This invention belongs to the field of biotechnology, specifically relating to an oyster peptide that enhances intestinal barrier function and improves intestinal inflammation, its preparation method, and its applications. The oyster peptide provided by this invention can alleviate colitis symptoms such as weight loss, colon shortening, and edema in mice, reduce disease activity index (DAI) levels, and regulate the balance of oxidative stress and inflammatory factors. Furthermore, LC-MS / MS technology was used to analyze the peptide sequence of the oyster peptide. Through this precise analytical process, key small molecule peptides with significant effects on enhancing intestinal barrier function and improving intestinal inflammation were successfully screened. This discovery provides important evidence for a deeper understanding of the effects of oyster peptides on enhancing intestinal barrier function and improving intestinal inflammation, and also provides new ideas for subsequent drug development and clinical treatment.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of Atractylodes macrocephala ethyl acetate extract in the preparation of drugs for treating acute ulcerative colitis. The Atractylodes macrocephala extract is prepared by the following method: Atractylodes macrocephala is soaked overnight in a 60%–80% (v / v) ethanol solution, then refluxed at 90–110°C for 2–3 times, 1–3 hours each time, at a material-to-liquid ratio of 0.5–1.5:10–15 (kg / L), for 1–3 hours each time. The extracts are combined and concentrated to obtain a total extract. The total extract is then dissolved in water and extracted 2–3 times with an equal volume of ethyl acetate. The extracts are combined, concentrated, and dried to obtain the final extract. Animal experiments show that this extract can significantly improve the symptoms of DSS-induced ulcerative colitis in mice, reduce the disease activity index, alleviate pathological damage to colonic tissue, inhibit the expression of inflammatory factors, and protect intestinal barrier function, demonstrating good therapeutic potential.

The present application relates to the technical field of prevention and treatment of intestinal inflammatory diseases, and in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the present application is an active heptapeptide derived from a natural protein, has a clear chemical structure and a reproducible preparation process. Research results show that the polypeptide can significantly improve the symptoms of ulcerative colitis induced by dextran sodium sulfate (DSS) in mice, including reducing body weight loss, reducing disease activity index (DAI), restoring colon length, improving colon tissue pathological damage and inhibiting inflammation-related signaling pathways, thereby verifying its improvement effect on intestinal inflammation. By preparing the polypeptide into a pharmaceutical composition, a comprehensive effect of prevention and treatment, inflammation improvement and barrier repair in parallel can be achieved, thereby providing a new strategy and material basis for the prevention and treatment of ulcerative colitis and other intestinal inflammatory diseases.